Low Dose Naltrexone (LDN) for Cancer: Evidence Review

The Bottom Line

Low Dose Naltrexone (LDN) refers to naltrexone at 1.5-4.5mg nightly, roughly 1/10th to 1/20th of the standard 50mg dose used for addiction treatment. At these low doses, naltrexone briefly blocks opioid receptors, triggering a compensatory rebound increase in endorphins and enkephalins. These endogenous opioids interact with opioid growth factor receptor (OGFr) signaling on immune cells and cancer cells, promoting immune surveillance and inhibiting tumor cell proliferation. The mechanism is biologically plausible and well-characterized. Clinical evidence consists of case reports, small pilot studies, and ongoing trials. There are no large published RCTs yet, but several are in progress.

What It Is

Naltrexone is an opioid receptor antagonist FDA-approved since 1984 for alcohol and opioid dependence at 50mg/day. LDN uses 1.5-4.5mg taken at bedtime. The idea was pioneered by Dr. Bernard Bihari in the 1980s, who observed immune-modulating effects at low doses in HIV/AIDS patients. Its use has since expanded to autoimmune conditions, chronic pain, and cancer. Naltrexone is off-patent and costs roughly $15-40/month from compounding pharmacies.

How It Works Against Cancer

• Endorphin rebound: Brief nighttime opioid receptor blockade triggers a compensatory 2-3x increase in beta-endorphin and met-enkephalin levels by morning. These endogenous opioids persist at elevated levels throughout the day.
• Opioid Growth Factor Receptor (OGFr): Met-enkephalin (also called Opioid Growth Factor, OGF) binds OGFr on cancer cells, directly inhibiting DNA synthesis and cell proliferation. This pathway has been extensively characterized by Dr. Ian Zagon's lab at Penn State.
• Immune enhancement: Elevated endorphins increase NK cell activity, T-cell function, and macrophage activation. Cancer patients typically have low endorphin levels. LDN may restore this immune deficit.
• Anti-inflammatory: Reduces pro-inflammatory cytokines (IL-6, TNF-alpha) that promote tumor growth and immune evasion.
• TLR4 antagonism: At low doses, naltrexone acts as a Toll-like Receptor 4 (TLR4) antagonist, reducing neuroinflammation and potentially modulating the tumor microenvironment.

The Evidence

The Zagon/Lab Research — Strong Preclinical

Dr. Ian Zagon at Penn State has published extensively on the OGF-OGFr axis in cancer:

• Demonstrated OGF inhibits growth of pancreatic, colon, breast, ovarian, and brain tumors in animal models
• Showed that blocking OGFr eliminates the anti-tumor effect, confirming the mechanism
• Published a Phase I trial of LDN in pancreatic cancer (safe, some signals of benefit)
• The OGFr pathway is one of the best-characterized growth regulatory systems in cancer biology

Clinical Evidence — Limited but Growing

• Pancreatic cancer Phase I (Zagon et al.): LDN was safe and well-tolerated. Some patients showed stable disease or partial response. Small sample size prevents definitive conclusions.
• Bihari case series: Dr. Bihari reported improved outcomes in hundreds of cancer patients using LDN, but these were uncontrolled observations.
• Ongoing trials: Clinical trials are registered for LDN in multiple cancer types including breast cancer and glioblastoma.
• Autoimmune evidence: LDN has more robust clinical data in autoimmune conditions (multiple sclerosis, fibromyalgia, Crohn's disease), confirming its immunomodulatory effects in humans.

Anecdotal and Case Report Evidence

There are numerous patient reports of tumor stabilization or regression on LDN, often combined with other treatments. These are impossible to attribute to LDN alone but are consistent with the mechanism.

Evidence Grade: C — Early / Limited

The OGF-OGFr mechanism is well-characterized in preclinical models. The drug is safe and cheap. But clinical trial data in cancer patients is thin, consisting of a Phase I safety trial and uncontrolled case series. We need Phase II RCTs. The autoimmune data gives us confidence that LDN does modulate the immune system in humans, which is encouraging.

Protocol Considerations

• Dose: 1.5-4.5mg at bedtime (typically started at 1.5mg and titrated up)
• Timing: Must be taken at night to exploit the endorphin rebound cycle
• Sourcing: Requires a compounding pharmacy (standard naltrexone pills are 50mg, too large to accurately split)
• Cost: $15-40/month from compounding pharmacies
• Contraindicated with: Opioid pain medications (will block their effect), active opioid dependence
• Duration: Most protocols use LDN indefinitely as a long-term adjunct

Safety Profile

• Extremely well-tolerated at LDN doses. The 50mg dose has been used safely in millions of patients.
• Common side effects at LDN doses: Vivid dreams (very common, usually benign), temporary sleep disruption during first 1-2 weeks
• Rare: Headache, nausea, muscle aches (typically resolve within days)
• Main caution: Will block opioid medications. Patients on opioid pain management should not use LDN without careful medical supervision.

LDN in Context

LDN fits into a category of repurposed drugs that modulate the immune system rather than directly killing cancer cells. Unlike chemotherapy or targeted therapy, LDN works by removing immunosuppressive brakes and amplifying the body's own anti-tumor defenses. This makes it theoretically synergistic with immunotherapy drugs like checkpoint inhibitors, though this combination has not been formally studied.

Our Assessment

LDN has one of the most biologically plausible mechanisms among repurposed cancer drugs. The OGF-OGFr pathway is real, well-characterized, and directly relevant to cancer cell growth control. The drug is exceptionally safe and cheap. The missing piece is clinical trial data. For cancer patients looking for low-risk adjuncts, LDN is a reasonable consideration, especially given its minimal side effect profile. It should not replace standard treatment. It may complement immunotherapy, but this needs formal study. The main barrier is access via compounding pharmacies and the need to avoid opioid medications.

Sources

• Zagon IS, McLaughlin PJ. Pharmacological Reviews 2021;73(3):948 — OGF-OGFr axis in cancer comprehensive review
• Zagon IS et al. Cancer Chemotherapy and Pharmacology 2017 — LDN Phase I pancreatic cancer trial
• McLaughlin PJ, Zagon IS. Expert Opinion on Biological Therapy 2018 — OGFr as cancer target
• Berkowitz RL et al. Journal of Clinical Oncology 2014 — LDN immune modulation review
• Cantor J et al. Clinical Therapeutics 2018 — LDN and TLR4 antagonism